Eyconis uses the TransCon prodrug platform to create long‑acting, sustained‑release formulations of ophthalmic medicines, enabling controlled drug delivery inside the eye for months to years. By covalently linking active agents to a biodegradable carrier, the company aims to reduce the frequency of intravitreal injections for retinal diseases such as wet AMD, diabetic macular edema, retinal vein occlusion, and geographic atrophy, improving patient adherence and visual outcomes.
Funding
$25M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with retinal diseases such as wet age‑related macular degeneration, diabetic macular edema, retinal vein occlusion, and geographic atrophy require frequent intravitreal injections of biologics, leading to high treatment burden, adherence challenges, and suboptimal outcomes.
Solution
Eyconis leverages an exclusive worldwide license to the TransCon technology platform to create long‑acting, sustained‑release formulations of clinically validated and emerging ophthalmic medicines. By covalently linking active drug molecules to a biodegradable carrier, TransCon enables controlled release over extended periods, reducing injection frequency while maintaining therapeutic exposure. The platform is adaptable to multiple drug classes, allowing Eyconis to develop best‑in‑class therapies across the major causes of blindness. This approach aims to improve patient convenience, adherence, and visual outcomes while delivering value to healthcare systems.
Target Audience
Primary customers are pharmaceutical companies developing retinal disease therapeutics and ophthalmologists seeking longer‑acting treatment options for patients with AMD, DME, RVO, and GA.
Features
- TransCon prodrug platform that provides sustained intra‑ocular release of active agents for months to years
- Compatibility with a broad range of biologics and small‑molecule ophthalmic drugs
- Proprietary chemistry enabling precise control of release kinetics and drug stability
- Scalable manufacturing process designed for ophthalmic formulation and sterile fill‑finish
- Preclinical and early clinical data supporting reduced injection frequency without loss of efficacy